Transition Bio

Private

Cambridge, MassachusettsHealthcare & Life Scienceshttps://transitionbio.com/

Last Round

Series B

Oct 30, 2024

Total Funding Raised

$72.3M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Transition Bio is a biotechnology company that develops a hypothesis-free drug discovery and diagnostics platform utilizing droplet microfluidic techniques and protein biophysics to analyze biomolecular condensates.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

drug discoverybiomolecular condensatescondensomicsdroplet microfluidicssmall-molecule therapeuticsAI drug discoverybiotech platformundruggable targetscellular imagingin silico drug designprotein mislocalizationAI-first biotechtherapeutic pipelinehigh-throughput screeningtechbio

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Transition Bio Comps

Public and private peers based on sector, stage, and business model.

Transition Bio comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Transition Bio Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Oct 30, 2024
Seed Round	Jan 10, 2024
Series A	Jun 2, 2022
Seed	Sep 1, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Martin Kulander

Co-President COO

Executive Team

Transition Bio Investors

Notable investors and investment history

Transition Bio investors
Investor	Rounds
Magnetic Ventures	Series A
Magnetic Ventures	Series A, Series B
Taiho Ventures	Series A
Lifeforce Capital	Series A, Series B, Seed
Northpond Ventures	Series A
Cambridge Enterprise	Seed, Series A
Northpond Ventures	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 27, 2026
Close affiliation disclosed with University of Cambridge and Harvard.
Sep 1, 2020
Completed a Seed funding round.

View all signals

Transition Bio Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Transition Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Transition Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts

Employee Range29

Year Founded2020

Last FundingOct 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.